Market research
22Z.F Zealand Pharma A/S
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- 7.17
- Analyst target
- 222.65
- Dividend yield
- Not available
- Beta
- 0.59
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- DK0060257814
- Market cap
- 3B
- P/E ratio
- 7.17
- Analyst target
- 222.65
- Dividend yield
- Not available
- Beta
- 0.59
About
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 22Z.F discussion.
5 years, 5 months ago
Zealand Pharma A/S is currently in a long term downtrend where the price is trading 7.8% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.0.
Zealand Pharma A/S's total revenue rose by 451.3% to $63M since the same quarter in the previous year.
Its net income has dropped by 96.5% to $-381M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.4% to $-277M since the same quarter in the previous year.
Based on the above factors, Zealand Pharma A/S gets an overall score of 2/5.